Systemic sclerosis & Raynaud's
Does therapy with immunosuppressive drugs improve gastrointestinal symptoms in patients with systemic sclerosis?
Authors' conclusion
Immunosuppressive treatment was associated with lower GIT scores in our cohort, which suggests the potential effects of immunosuppressants on GI manifestations in patients with SSc
Study context
- Population
- Systemic sclerosis (SSc) patients with at least two visits with completed GITs within 12±3 months (82.3% female, median age 59.0 years, median disease duration 6.0 years, 40 (19.1%) diffuse cutaneous SSc, median baseline GIT 0.19)
- Participants
- 209 patients
- Exposure
- Immunosuppressive therapy during observation vs no immunosuppressive therapy
- Immunosuppressive therapyn = 71
- Outcome
- GIT score (UCLA SCTC GIT 2.0) at follow-up
- Follow-up
- 12±3 months
Methodological detailsmultivariable linear regression
- Multivariable linear regression
Main finding
As reported in the abstract
GIT score at follow-up
- Immunosuppressive therapy during observation significantly associated with lower (better) GIT scores at follow-up (multivariable linear regression)
- Lower baseline GIT scores significantly associated with lower GIT scores at follow-up
Observational data: associations, not effects.
Further findings
Baseline characteristics of exposed vs unexposed
- Exposed had overall more severe SSc and a higher prevalence of proton pump inhibitor treatment
Original publication
Does therapy with immunosuppressive drugs improve gastrointestinal symptoms in patients with systemic sclerosis? RMD Open. Published 24 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →